NVSEF - Novartis weighs listing of $25B generic unit - Bloomberg

• Swiss drugmaker, Novartis AG ( NYSE: NVS ) ( OTCPK:NVSEF ) is said to be leaning towards a potential spinoff of its Sandoz business and a separate listing of the $25B generics drug unit is increasingly likely, Bloomberg reported Thursday citing people familiar with the matter
• The plans reflect the challenging environment for leveraged buyouts which makes a potential sale to private equity more difficult.
• In October, The Wall Street Journal reported that Novartis AG ( NVS ) had started a strategic review of Sandoz, targeting a sale or spinoff of the unit.
• A spokesman for Novartis ( NVS ) noted that the strategic review continues to advance, and all options are currently under consideration. An update on the process is expected by the year end.

For further details see: